anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 64
Group description: 0.9% Sodium Chloride- 100ml

0.9% sodium chloride: Sodium chloride 0.9%- 47.7 ml
Eligibility criteria:
Inclusion Criteria:

Age 18 or older
Written informed consent

Exclusion Criteria:

Pregnant women
Creatinine clearance less than 60 ml/min
BMI greater than 40
Currently use greater than 80mg morphine-equivalents daily (pre-operatively)
Receive a unicondylar knee replacement
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 135
Group description: Normal saline 0.9% (5 mL)

Normal saline: Intravenous normal saline 0.9% 5 mL
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists physical status I or II
Patients scheduled to undergo laparoscopic cholecystectomy

Exclusion Criteria:

Patients who refuse to participate in the study
Patients who are not able to communicate due to alterations in the level of consciousness, or neurologic, or psychiatric disease
Contraindication of any of the drugs used in the study
Patients who are superobese (BMI>40)
History of alcohol or drug dependence
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 135
Group description: ketamine 0.2 mg/kg (5 mL)

Ketamine 0.2 mg/kg: Intravenous ketamine 0.2 mg/kg after induction of anesthesia
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists physical status I or II
Patients scheduled to undergo laparoscopic cholecystectomy

Exclusion Criteria:

Patients who refuse to participate in the study
Patients who are not able to communicate due to alterations in the level of consciousness, or neurologic, or psychiatric disease
Contraindication of any of the drugs used in the study
Patients who are superobese (BMI>40)
History of alcohol or drug dependence
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 135
Group description: ketamine 0.4 mg/kg (5 mL)

Ketamine 0.4 mg/kg: Intravenous ketamine 0.4 mg/kg after induction of anesthesia
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists physical status I or II
Patients scheduled to undergo laparoscopic cholecystectomy

Exclusion Criteria:

Patients who refuse to participate in the study
Patients who are not able to communicate due to alterations in the level of consciousness, or neurologic, or psychiatric disease
Contraindication of any of the drugs used in the study
Patients who are superobese (BMI>40)
History of alcohol or drug dependence
Intervention: Fentanyl Citrate
Trial phase: Phase 4
SMILES: CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Open label, no blinding, everyone receives Lazanda.

Lazanda: Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.

There were no adverse events.
Eligibility criteria:
Inclusion Criteria:

Male and female patients ASA(American Society of Anesthesiologist physical classification system) I-III
18 years of age and older Referred for lumbar facet RFA (radio-frequency ablation) by Womack IPMC (Interdisciplinary Pain Management Center)

Exclusion Criteria:

Known allergy to Fentanyl or naloxone
Diagnoses of allergic rhinitis with active rhinorrhea
Pregnant or Breastfeeding
Asthma or COPD (chronic obstructive pulmonary disease) that requires frequent rescue medications.
Hepatic insufficiency with abnormal liver enzymes
Noted decreased mental function
Heart rate under 50 or BP below 90 systolic and/or 60 diastolic
Myasthenia gravis diagnoses
Acute narrow angle glaucoma
Allergy to meperidine
On medications with a known dangerous drug interactions to Fentanyl
Intervention: Dorzolamide Hydrochloride
Trial phase: Phase 2
SMILES: CCNC1CC(C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.
Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.
Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits
At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients

Dorzolamide-timolol: On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
Eligibility criteria:
Inclusion Criteria:

Patient of Wills Eye Hospital Retina Service and/or Mid Atlantic Retina.
Volunteer patients age 18 years and older.
Healthy enough to participate in the study.
Willing and able to consent to participation in the study.
Diagnosis of wet age-related macular degeneration
Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period
Injection of the same anti-VEGF agent for at least two visits prior to study enrollment
Fixed interval between at least two visits prior to study enrollment

Exclusion Criteria:

History of uveitis
Any ophthalmic surgery within previous 6 months, including cataract extraction.
Any history of vitrectomy
History of any glaucoma drop usage or prior glaucoma surgery
Systemic diuretic or corticosteroid usage
Any contraindication (bradycardia, decompensated heart failure, or reactive
airway disease) for topical use of a beta-blocker

Any history of sulfonamide allergy

-
Intervention: Umibecestat
Trial phase: Phase 2
SMILES: CC1(c2nc(NC(=O)c3ncc(C(F)(F)F)cc3Cl)ccc2F)COC(C)(C(F)(F)F)C(N)=N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: CNP520 2 mg was taken qd orally for 13 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Healthy status
Body weight: ≥45kg
BMI: 18-34 kg/m2

Key Exclusion Criteria:

History or presence of any clinically significant disease of any major system organ class.
Heavy smoker status
History /presence of clinically significant neurological or psychiatric disorders
Any medical condition that might lead to or is associated with any cognitive deficit
History or presence of severely impaired renal function
Intervention: Umibecestat
Trial phase: Phase 2
SMILES: CC1(c2nc(NC(=O)c3ncc(C(F)(F)F)cc3Cl)ccc2F)COC(C)(C(F)(F)F)C(N)=N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: CNP520 10 mg was taken qd orally for 13 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Healthy status
Body weight: ≥45kg
BMI: 18-34 kg/m2

Key Exclusion Criteria:

History or presence of any clinically significant disease of any major system organ class.
Heavy smoker status
History /presence of clinically significant neurological or psychiatric disorders
Any medical condition that might lead to or is associated with any cognitive deficit
History or presence of severely impaired renal function
Intervention: Umibecestat
Trial phase: Phase 2
SMILES: CC1(c2nc(NC(=O)c3ncc(C(F)(F)F)cc3Cl)ccc2F)COC(C)(C(F)(F)F)C(N)=N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 26
Group description: CNP520 35 mg was taken qd orally for 13 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Healthy status
Body weight: ≥45kg
BMI: 18-34 kg/m2

Key Exclusion Criteria:

History or presence of any clinically significant disease of any major system organ class.
Heavy smoker status
History /presence of clinically significant neurological or psychiatric disorders
Any medical condition that might lead to or is associated with any cognitive deficit
History or presence of severely impaired renal function
Intervention: ULIPRISTAL ACETATE
Trial phase: Phase 4
SMILES: CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 36
Group description: During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.

Ulipristal Acetate
Eligibility criteria:
Inclusion Criteria:

Generally healthy women aged 18 to 35 with regular menses (every 21-35 days).
Normal BMI
Proven ovulation with a screening serum progesterone of >3ng/mL
Willing to use condoms (if sexually active with a male partner), willing to not have sex with men during the study, or have had a tubal ligation (or have a partner who has had a vasectomy) or have a copper intrauterine device (IUD).

Exclusion Criteria:

Known intolerance or allergy to any of the study medication
Known metabolic disorders including polycystic ovarian syndrome or uncontrolled thyroid disorder
Overweight or obese BMI
Any Centers for Disease Control and Prevention (CDC) Medical eligibility criteria category 3 or 4 for combined oral contraception (COC) use 12.
Pregnancy, breastfeeding, or seeking pregnancy; recent (8 week) use of hormonal contraception
Current use of drugs that interfere with metabolism of sex steroids
Smokers.
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: 10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate

Decadron: 10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
Eligibility criteria:
Inclusion Criteria:

All patients undergoing ACDF (single or multi-level) for the treatment of cervical radiculopathy or myelopathy
All subjects must have given signed, informed consent prior to registration on study.

Exclusion Criteria:

Patients undergoing revision surgery, any operations for trauma, infection, tumor
Patients with general metabolic diseases such as rheumatoid arthritis, diabetes, chronic heart and renal diseases.
Intervention: Triamcinolone
Trial phase: Not Applicable
ATC code: A01AC01 | C05AA12 | D07AB09 | D07BB03 | D07CB01 | D07XB02 | H02AB08 | R01AD11 | R03BA06 | S01BA05 | S02CA04
SMILES: [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: 40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate

Triamcinolone: 40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
Eligibility criteria:
Inclusion Criteria:

All patients undergoing ACDF (single or multi-level) for the treatment of cervical radiculopathy or myelopathy
All subjects must have given signed, informed consent prior to registration on study.

Exclusion Criteria:

Patients undergoing revision surgery, any operations for trauma, infection, tumor
Patients with general metabolic diseases such as rheumatoid arthritis, diabetes, chronic heart and renal diseases.
Intervention: Diphenhydramine Hydrochloride
Trial phase: Phase 4
SMILES: CN(C)CCOC(c1ccccc1)c1ccccc1.Cl
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep

Diphenhydramine Hydrochloride: 30 mL at bedtime
Eligibility criteria:
Inclusion Criteria:

be male or female subjects, ≥18 years of age to 55 years of age, who report that they are currently experiencing occasional sleeplessness characterized by difficulty initiating sleep (ie, taking ≥30 minutes to fall asleep) on average 2-4 times per week for less than 1 month;
be in good general health without clinically significant disease (no previously diagnosed sleep disorders);
if female, have a negative screening pregnancy test and agree to be on approved methods of birth control throughout the study

Exclusion Criteria:

have a clinically significant illness within 30 days of Screening;
are taking medication that could interfere with the study medication;
have been under a clinician's care for insomnia treatment and control within the past year or has a history of insomnia or is currently taking prescription medications for insomnia;
are currently taking medications known to effect sleep function;
have current or past history of serious, severe or unstable physical or psychiatric illness;
have current diagnosis of severe urinary retention;
have current diagnosis of untreated narrow angle glaucoma;
had participated in a clinical drug study or used an investigational new drug during the previous 30 days;
have any clinically significant or abnormal finding in physical examination, vital signs, ECG, or clinical laboratory tests that may affect the subject's safety or outcome of the study;
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 72
Group description: Intravenous propofol for maintenance of anesthesia

Propofol
Eligibility criteria:
Inclusion Criteria:

Patients undergoing endoscopic sinus surgery
Advanced inflammatory sinus disease, defined as allergic fungal sinusitis, chronic rhinosinusitis with nasal polyposis, chronic rhinosinusitis with eosinophilia, or rhinosinusitis with pan-sinus opacification (Lund-Mackay score >12).

Exclusion Criteria:

Noninflammatory sinonasal disease
Disease extending through the skull base or orbital wall
American Society of Anesthesiologists Preoperative Health Status >II
Known non-pharmacologic coagulopathy (platelet < 50000/mL, international normalized ratio > 1.2)
Preoperative anticoagulants within 7 days of surgery
Allergy to one of the study medications
Age under 18 years
Non-English-speaking
Intervention: Isoflurane
Trial phase: Phase 4
ATC code: N01AB06
SMILES: FC(F)OC(Cl)C(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 72
Group description: Inhaled volatile anesthetic for maintenance of anesthesia

Sevoflurane
Eligibility criteria:
Inclusion Criteria:

Patients undergoing endoscopic sinus surgery
Advanced inflammatory sinus disease, defined as allergic fungal sinusitis, chronic rhinosinusitis with nasal polyposis, chronic rhinosinusitis with eosinophilia, or rhinosinusitis with pan-sinus opacification (Lund-Mackay score >12).

Exclusion Criteria:

Noninflammatory sinonasal disease
Disease extending through the skull base or orbital wall
American Society of Anesthesiologists Preoperative Health Status >II
Known non-pharmacologic coagulopathy (platelet < 50000/mL, international normalized ratio > 1.2)
Preoperative anticoagulants within 7 days of surgery
Allergy to one of the study medications
Age under 18 years
Non-English-speaking
Intervention: Intralipid
Trial phase: Phase 3
SMILES: CCCCCC=CCC=CCCCCCCCC(=O)O.CCCCCCCCC=CCCCCCCCC(=O)OC(COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OCC[N+](C)(C)C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 78
Group description: Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: "Solutions for parenteral nutrition, fat emulsions".

Intralipid® 20%: Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.

Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.

Intralipid® 20% will be infused into a central or peripheral vein.
Eligibility criteria:
Inclusion Criteria:

Neonates and infants, expected to require parenteral nutrition (PN) for 28 days
Postmenstrual age ≥ 24 weeks
Birth weight ≥ 750g
Gastroschisis, duodenal, jejunal or ileal atresia, volvulus, spontaneous intestinal perforation or necrotizing enterocolitis (Bell's stage 2B or higher)
At least 80% of nutritional needs at baseline received by PN
Signed and dated informed consent obtained from at least one parent or legal guardian

Exclusion Criteria:

Conjugated bilirubin > 0.6 mg/dL
Any known pre-, intra- or posthepatic complication increasing conjugated bilirubin levels > 0.6, mg/dL during study participation
Suspected liver disease or liver damage based on either aspartate aminotransferase (AST), alanine aminotransferase (ALT), or gamma-glutamyl transferase (GGT) exceeding 2.5x upper limit of normal range
Active bloodstream infection demonstrated by positive blood culture at screening
Cystic fibrosis
Meconium ileus
Serum triglyceride levels > 250 mg/dL
Cyanotic congenital heart defect
Severe renal failure with serum creatinine > 2.0 mg/dL
History of shock requiring vasopressors
Anasarca
Extracorporeal Membrane Oxygenation (ECMO)
Known inborn errors of metabolism
Known congenital viral infection
Unlikely to survive longer than 28 days
Known hypersensitivity to fish-, egg-, soya- or peanut protein or to any of the active substances or excipients
Intervention: Acetylcysteine
Trial phase: Phase 4
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.
Eligibility criteria:
Inclusion Criteria:

stable COPD with mild-to-moderate airflow obstruction as indicated by the low ratio between forced expiratory volume in one second and forced vital capacity (FEV1/FVC<0.7) together with post-bronchodilator FEV1≥60% predicted under optimized clinical treatment as judged by the accompanying physician

Exclusion Criteria:

unable to perform all experimental procedures and/or provide informed consent;
hospital admission in the previous 6 weeks;
exercise training program in the previous 6 months;
any condition that could interfere with the ability to exercise;
diagnosed psychiatric or cognitive disorders;
type I insulin-dependent diabetes mellitus;
excessively over-weight (BMI>35kg/m²);
other diagnosed cardiorespiratory disorders (e.g., chronic heart failure, peripheral artery disease).
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 17
Group description: Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).

Ketamine: A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
Eligibility criteria:
Inclusion:

MDD Cohort:

Meet DSM-5 criteria for Major Depressive Disorder by structured interview (MINI-KID)
CDRS-R score >40.
Failure to achieve remission with at least 1 adequate prior antidepressant trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.

Anxiety Cohort:

Meet DSM-5 criteria for any of the following anxiety disorders: Social Anxiety Disorders, Generalized Anxiety Disorder, Separation Anxiety Disorder and/or Panic Disorder by structured interview (MINI-KID)
ADIS Clinical Severity Rating ≥4 (moderately severe) for any of the 4 included anxiety disorders
Failure to achieve remission with at least 1 adequate prior anxiolytic medication trial (e.g. SSRI, SNRI, or TCA), meaning at least 8 weeks at therapeutic dosing, including at least 4 weeks of stable dosing.
Failure to achieve remission with previous CBT or subject declines current CBT therapy

Both cohorts:

Stable psychiatric medications and doses for the month prior to enrollment. Subjects may continue to engage in any ongoing psychotherapy.
Medically and neurologically healthy on the basis of physical examination and medical history.
Parents able to provide written informed consent and adolescents must additionally provide assent.

Exclusion:

Current inpatient hospitalization or active suicidal ideation requiring referral for inpatient hospitalization for safety.
History of psychotic disorder or manic episode diagnosed by MINI-KID
History of substance dependence diagnosis by MINI-KID (excluding tobacco) or positive urine toxicology.
Pregnancy (urine pregnancy tests on the day of scans for menstruating girls).
Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.